INSMED Inc (INSM) stock
INSMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 8/30100% above fair value
$122.88+1.72 (+1.42%)
Close on Nov 16, 2026Market cap $26.96BP/E –Yield –
Insmed r&d expenses
Research and development expenses are spending on new products and technology.
Insmed's R&D Expenses for the twelve months ending Sep 30, 2026 was $944.39M, up 35.7% year over year. For fiscal 2025 it was $771.09M, up 28.9% from the year before. Over ten years it grew 26.4% a year on average. The highest annual figure on record is $771.09M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $771.09M | +28.9% |
| FY2024 | Dec 31, 2024 | $598.37M | +4.8% |
| FY2023 | Dec 31, 2023 | $571.01M | +43.6% |
| FY2022 | Dec 31, 2022 | $397.52M | +45.7% |
| FY2021 | Dec 31, 2021 | $272.74M | +50.6% |
| FY2020 | Dec 31, 2020 | $181.16M | +37.5% |
| FY2019 | Dec 31, 2019 | $131.71M | -9.3% |
| FY2018 | Dec 31, 2018 | $145.28M | +32.4% |
| FY2017 | Dec 31, 2017 | $109.75M | -10.6% |
| FY2016 | Dec 31, 2016 | $122.72M | +65.2% |
| FY2015 | Dec 31, 2015 | $74.28M | +31.9% |
| FY2014 | Dec 31, 2014 | $56.29M | +27.1% |
| FY2013 | Dec 31, 2013 | $44.28M | +48.7% |
| FY2012 | Dec 31, 2012 | $29.78M | +4.0% |
| FY2011 | Dec 31, 2011 | $28.62M | +508.7% |
| FY2010 | Dec 31, 2010 | $4.70M | -48.9% |
| FY2009 | Dec 31, 2009 | $9.21M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $269.96M | +44.8% |
| Q2 FY2026 | Jun 30, 2026 | $210.03M | +18.5% |
| Q1 FY2026 | Mar 31, 2026 | $209.49M | +37.3% |
| Q4 FY2025 | Dec 31, 2025 | $254.91M | +41.8% |
| Q3 FY2025 | Sep 30, 2025 | $186.42M | +23.6% |
| Q2 FY2025 | Jun 30, 2025 | $177.19M | +20.7% |
| Q1 FY2025 | Mar 31, 2025 | $152.58M | +26.0% |
| Q4 FY2024 | Dec 31, 2024 | $179.73M | +31.2% |
| Q3 FY2024 | Sep 30, 2024 | $150.81M | +38.2% |
| Q2 FY2024 | Jun 30, 2024 | $146.75M | -25.5% |
| Q1 FY2024 | Mar 31, 2024 | $121.08M | -5.3% |
| Q4 FY2023 | Dec 31, 2023 | $137.03M | +9.8% |
| Q3 FY2023 | Sep 30, 2023 | $109.15M | +9.3% |
| Q2 FY2023 | Jun 30, 2023 | $196.97M | +122.5% |
| Q1 FY2023 | Mar 31, 2023 | $127.87M | +51.6% |
| Q4 FY2022 | Dec 31, 2022 | $124.76M | +63.4% |
| Q3 FY2022 | Sep 30, 2022 | $99.87M | +42.0% |
| Q2 FY2022 | Jun 30, 2022 | $88.53M | +36.9% |
| Q1 FY2022 | Mar 31, 2022 | $84.36M | +37.4% |
| Q4 FY2021 | Dec 31, 2021 | $76.35M | +12.6% |
| Q3 FY2021 | Sep 30, 2021 | $70.35M | +69.9% |
| Q2 FY2021 | Jun 30, 2021 | $64.66M | +80.9% |
| Q1 FY2021 | Mar 31, 2021 | $61.39M | +69.7% |
| Q4 FY2020 | Dec 31, 2020 | $67.81M | +107.8% |
| Q3 FY2020 | Sep 30, 2020 | $41.41M | +20.6% |
| Q2 FY2020 | Jun 30, 2020 | $35.75M | +6.6% |
| Q1 FY2020 | Mar 31, 2020 | $36.18M | +16.0% |
| Q4 FY2019 | Dec 31, 2019 | $32.63M | -18.3% |
| Q3 FY2019 | Sep 30, 2019 | $34.34M | -13.1% |
| Q2 FY2019 | Jun 30, 2019 | $33.54M | -6.1% |
| Q1 FY2019 | Mar 31, 2019 | $31.20M | +3.7% |
| Q4 FY2018 | Dec 31, 2018 | $39.93M | +17.6% |
| Q3 FY2018 | Sep 30, 2018 | $39.54M | +48.2% |
| Q2 FY2018 | Jun 30, 2018 | $35.72M | +32.9% |
| Q1 FY2018 | Mar 31, 2018 | $30.10M | +35.2% |
| Q4 FY2017 | Dec 31, 2017 | $33.95M | -38.1% |
| Q3 FY2017 | Sep 30, 2017 | $26.68M | – |
| Q2 FY2017 | Jun 30, 2017 | $26.87M | – |
| Q1 FY2017 | Mar 31, 2017 | $22.25M | – |
| Q4 FY2016 | Dec 31, 2016 | $54.87M | – |
See a number that looks wrong?